Macrocyclic OMNI-EGFR Inhibitor
Non-Small Cell Lung Cancer (NSCLC)
Phase 1Active
Key Facts
About BlossomHill Therapeutics
BlossomHill Therapeutics is a private, clinical-stage biotech company focused on developing intelligently designed small molecule drugs for oncology and autoimmune disorders. The company's pipeline is anchored by a first-in-class macrocyclic OMNI-EGFR inhibitor for NSCLC and new pan-KRAS inhibitor programs, indicating a focus on high-value, difficult-to-drug targets. With an $84 million financing round closed in late 2025, BlossomHill is well-capitalized to advance its clinical-stage assets, positioning it as an emerging player in the precision oncology and autoimmune therapy landscape.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |
| OX-4224 | OmRx Oncology | Phase 2 |